VMD · Viemed Healthcare, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Viemed delivered record Q2 revenue and broad patient growth, prompting it to raise the low end of full-year revenue guidance and lower its net CapEx outlook. It also cut full-year Adjusted EBITDA guidance and reported lower Adjusted EBITDA, gross margin, and attributable net income amid investment and revenue-mix pressure.
- + Record Q2 revenue rose 23.9% year over year and 3.6% sequentially.
- + Ventilator patients reached a record 12,635, up 4.5% sequentially.
- + PAP therapy and sleep resupply patients grew strongly year over year and sequentially.
- + The company raised the low end of full-year net revenue guidance to $314 million–$320 million.
- + The company lowered its full-year net CapEx outlook to 8.5%–10.0% of net revenue.
- + First-half operating cash flow and free cash flow increased from the prior year.
- − Full-year Adjusted EBITDA guidance was cut to $64 million–$68 million.
- − Q2 Adjusted EBITDA declined 4.0% year over year and its margin fell to 17.6% from 22.7%.
- − Gross margin declined year over year amid revenue-mix and temporary maternal-health costs.
- − SG&A increased faster than revenue due to growth investments and temporary operating duplication.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VMD
this stock
Viemed Healthcare, Inc.
|
$339.37M | +24.4% | +20.5% | 24.8 | 3.5% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -8.4% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -18.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.5% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VMD | +1.4% | +1.8% | -4.8% | +1.5% | +24.4% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +0.2% | +1.2% | -16.4% | -0.1% | +10.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.